Efficacy and Safety of Initial Versus Delayed Verteporfin Photodynamic Therapy in Combination With Conbercept in Patients With Symptomatic Polypoidal Choroidal Vasculopathy

Trial Profile

Efficacy and Safety of Initial Versus Delayed Verteporfin Photodynamic Therapy in Combination With Conbercept in Patients With Symptomatic Polypoidal Choroidal Vasculopathy

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 06 Jan 2017

At a glance

  • Drugs Conbercept (Primary)
  • Indications Choroidal neovascularisation
  • Focus Therapeutic Use
  • Most Recent Events

    • 03 Jan 2017 Status changed from not yet recruiting to recruiting.
    • 14 Dec 2016 Planned primary completion date changed from 1 Jul 2017 to 1 Jan 2018.
    • 14 Dec 2016 Planned initiation date changed from 1 Jul 2016 to 1 Jan 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top